EditorialEditorial
Open Access

Multi-cancer early detection: from promise to practice and the next frontier

Yongjie Xu and Wanqing Chen
Cancer Biology & Medicine December 2025, 20250664; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0664

References

  1. 1.↵
    2. Aberle DR,
    3. Adams AM,
    4. Berg CD,
    5. Black WC,
    6. Clapp JD,
    7. Fagerstrom RM, et al.
    Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395–409.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Mittra I,
    3. Mishra GA,
    4. Dikshit RP,
    5. Gupta S,
    6. Kulkarni VY,
    7. Shaikh HKA, et al.
    Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai. BMJ. 2021; 372: n256.
  3. 3.↵
    2. Xia C,
    3. Li H,
    4. Xu Y,
    5. Guo G,
    6. Yu X,
    7. Wang W, et al.
    Effect of an endoscopy screening on upper gastrointestinal cancer mortality: a community-based multicenter cluster randomized clinical trial. Gastroenterology. 2025; 168: 725–40.
    OpenUrlPubMed
  4. 4.↵
    2. Xu Y,
    3. Zhu S,
    4. Xia C,
    5. Yu H,
    6. Shi S,
    7. Chen K, et al.
    Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation. Sci Bull (Beijing). 2025; 70: 2852–67.
    OpenUrlPubMed
  5. 5.↵
    2. Croswell JM,
    3. Kramer BS,
    4. Kreimer AR,
    5. Prorok PC,
    6. Xu JL,
    7. Baker SG, et al.
    Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009; 7: 212–22.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    2. Wu L,
    3. Qu X.
    Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015; 44: 2963–97.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Klein EA,
    3. Richards D,
    4. Cohn A,
    5. Tummala M,
    6. Lapham R,
    7. Cosgrove D, et al.
    Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32: 1167–77.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Schrag D,
    3. Beer TM,
    4. McDonnell CH 3rd.,
    5. Nadauld L,
    6. Dilaveri CA,
    7. Reid R, et al.
    Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023; 402: 1251–60.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Neal RD,
    3. Johnson P,
    4. Clarke CA,
    5. Hamilton SA,
    6. Zhang N,
    7. Kumar H, et al.
    Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial. Cancers (Basel). 2022; 14: 4818.
    OpenUrlPubMed
  10. 10.↵
    2. Gao Q,
    3. Lin YP,
    4. Li BS,
    5. Wang GQ,
    6. Dong LQ,
    7. Shen BY, et al.
    Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies. Ann Oncol. 2023; 34: 486–95.
    OpenUrlPubMed
  11. 11.↵
    2. He X,
    3. Ma S,
    4. Xu H,
    5. Li Z,
    6. Cai Y,
    7. Li Y, et al.
    Development and clinical validation of a cell-free DNA methylation sequencing test for multi-cancer early detection. J Clin Oncol. 2025; 43: 10537.
  12. 12.↵
    2. Bao H,
    3. Wang Z,
    4. Ma X,
    5. Guo W,
    6. Zhang X,
    7. Tang W, et al.
    Letter to the editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection. Mol Cancer. 2022; 21: 129.
    OpenUrlPubMed
  13. 13.↵
    2. Bao H,
    3. Yang S,
    4. Chen X,
    5. Dong G,
    6. Mao Y,
    7. Wu S, et al.
    Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics. Nat Med. 2025; 31: 2737–45.
    OpenUrlPubMed
  14. 14.↵
    2. Cohen JD,
    3. Li L,
    4. Wang Y,
    5. Thoburn C,
    6. Afsari B,
    7. Danilova L, et al.
    Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018; 359: 926–30.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    2. In ‘t Veld SGJG,
    3. Arkani M,
    4. Post E,
    5. Antunes-Ferreira M,
    6. D’Ambrosi S,
    7. Vessies DCL, et al.
    Detection and localization of early- and late-stage cancers using platelet RNA. Cancer Cell. 2022; 40: 999–1009.e6.
    OpenUrlPubMed
  16. 16.↵
    2. Zhang H,
    3. Zhao L,
    4. Jiang J,
    5. Zheng J,
    6. Yang L,
    7. Li Y, et al.
    Multiplexed nanomaterial-assisted laser desorption/ionization for pan-cancer diagnosis and classification. Nat Commun. 2022; 13: 617.
    OpenUrlPubMed
  17. 17.↵
    2. Luan Y,
    3. Zhong G,
    4. Li S,
    5. Wu W,
    6. Liu X,
    7. Zhu D, et al.
    A panel of seven protein tumour markers for effective and affordable multi-cancer early detection by artificial intelligence: a large-scale and multicentre case-control study. EClinicalMedicine. 2023; 61: 102041.
  18. 18.
    2. Cristiano S,
    3. Leal A,
    4. Phallen J,
    5. Fiksel J,
    6. Adleff V,
    7. Bruhm DC, et al.
    Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019; 570: 385–9.
    OpenUrlCrossRefPubMed
  19. 19.
    2. Kim SY,
    3. Jeong S,
    4. Lee W,
    5. Jeon Y,
    6. Kim YJ,
    7. Park S, et al.
    Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection. Exp Mol Med. 2023; 55: 2445–60.
    OpenUrlPubMed
  20. 20.↵
    2. Junca A,
    3. Tachon G,
    4. Evrard C,
    5. Villalva C,
    6. Frouin E,
    7. Karayan-Tapon L, et al.
    Detection of colorectal cancer and advanced adenoma by liquid biopsy (Decalib Study): the ddPCR challenge. Cancers (Basel). 2020; 12: 1482.
    OpenUrlPubMed
  21. 21.↵
    2. Etzioni R,
    3. Gulati R,
    4. Patriotis C,
    5. Rutter C,
    6. Zheng Y,
    7. Srivastava S, et al.
    Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies. J Natl Cancer Inst. 2024; 116: 189–93.
    OpenUrlPubMed
  22. 22.↵
    1. U.S. Food & Drug Administration
    . Use of circulating tumor DNA for curative-intent solid tumor drug development guidance for industry. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-guidance (Accessed: October 24, 2025).
  23. 23.↵
    2. Xia C,
    3. Xu Y,
    4. Li H,
    5. He S,
    6. Chen W.
    Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis. Lancet Reg Health West Pac. 2024; 44: 101012.
  24. 24.↵
    2. Xu Y,
    3. Xia C,
    4. Tong S,
    5. Yu H,
    6. Liu F,
    7. Chen S, et al.
    CanRisk-DB: an artificial intelligence-driven comprehensive database of cancer risk factors. NPJ Precis Oncol. 2025; 9: 377.
    OpenUrlPubMed
  25. 25.↵
    2. Webb AB,
    3. Berg CD,
    4. Castle PE,
    5. Crosby D,
    6. Etzioni R,
    7. Kessler LG, et al.
    Considerations for using potential surrogate endpoints in cancer screening trials. Lancet Oncol. 2024; 25: e183–92.
    OpenUrlPubMed
  26. 26.↵
    2. Hubbell E,
    3. Clarke CA,
    4. Aravanis AM,
    5. Berg CD.
    Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021; 30: 460–8.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Lipscomb J,
    3. Horton S,
    4. Kuo A,
    5. Tomasetti C.
    Evaluating the impact of multicancer early detection testing on health and economic outcomes: toward a decision modeling strategy. Cancer. 2022; 128: 892–908.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section